NasdaqGS - Delayed Quote USD

Cytek Biosciences, Inc. (CTKB)

2.6700
-0.0100
(-0.37%)
At close: 4:00:01 PM EDT
2.6700
0.00
(0.00%)
After hours: 4:18:10 PM EDT
Loading Chart for CTKB
  • Previous Close 2.6800
  • Open 2.6600
  • Bid 1.9300 x 200
  • Ask 3.2500 x 200
  • Day's Range 2.5200 - 2.6800
  • 52 Week Range 2.5200 - 7.6300
  • Volume 1,430,654
  • Avg. Volume 837,300
  • Market Cap (intraday) 338.18M
  • Beta (5Y Monthly) 1.42
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0900
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.60

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

cytekbio.com

663

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CTKB

View More

Performance Overview: CTKB

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CTKB
58.86%
S&P 500 (^GSPC)
1.30%

1-Year Return

CTKB
56.80%
S&P 500 (^GSPC)
12.48%

3-Year Return

CTKB
73.03%
S&P 500 (^GSPC)
48.66%

5-Year Return

CTKB
86.72%
S&P 500 (^GSPC)
108.07%

Compare To: CTKB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CTKB

View More

Valuation Measures

Annual
As of 5/15/2025
  • Market Cap

    340.08M

  • Enterprise Value

    90.36M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    0.90

  • Enterprise Value/Revenue

    0.46

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.71%

  • Return on Assets (ttm)

    -3.51%

  • Return on Equity (ttm)

    -2.91%

  • Revenue (ttm)

    197.05M

  • Net Income Avi to Common (ttm)

    -11.25M

  • Diluted EPS (ttm)

    -0.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    265.61M

  • Total Debt/Equity (mrq)

    4.19%

  • Levered Free Cash Flow (ttm)

    30.18M

Research Analysis: CTKB

View More

Company Insights: CTKB

Research Reports: CTKB

View More

People Also Watch